Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Munder

Showing results (61-70 of 88) with videos related to

Pageof 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2022
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III TrialPieter Sonneveld, Asher Chanan-Khan, Katja Weisel, et al.
Blood Cancer Journal|January 4, 2023
Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myelomaElias K Mai, Stefanie Huhn, Kaya Miah, et al.
Blood Cancer Journal|January 31, 2019
Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patientsKatharina Kriegsmann, Marc-Andrea Baertsch, Mohamed H S Awwad, et al.
Advances in Therapy|January 21, 2021
Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab MonotherapyAjai Chari, Markus Munder, Katja Weisel, et al.
Haematologica|August 20, 2016
Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trialMaximilian Merz, Hans Salwender, Mathias Haenel, et al.
Computers in Biology and Medicine|March 17, 2023
A drug repurposing approach for individualized cancer therapy based on transcriptome sequencing and virtual drug screeningOnat Kadioglu, Faranak Bahramimehr, Mona Dawood, et al.
Leukemia|July 1, 2018
Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myelomaElias K Mai, Thomas Hielscher, Uta Bertsch, et al.
Leukemia|November 4, 2021
Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trialLisa B Leypoldt, Britta Besemer, Anne Marie Asemissen, et al.
Leukemia|February 18, 2021
Selective elimination of immunosuppressive T cells in patients with multiple myelomaMohamed H S Awwad, Abdelrahman Mahmoud, Heiko Bruns, et al.
Haematologica|April 5, 2015
Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trialMaximilian Merz, Hans Salwender, Mathias Haenel, et al.
Pageof 9

Showing results (61-70 of 88) with videos related to

Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2022
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III TrialPieter Sonneveld, Asher Chanan-Khan, Katja Weisel, et al.
Blood Cancer Journal|January 4, 2023
Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myelomaElias K Mai, Stefanie Huhn, Kaya Miah, et al.
Blood Cancer Journal|January 31, 2019
Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patientsKatharina Kriegsmann, Marc-Andrea Baertsch, Mohamed H S Awwad, et al.
Advances in Therapy|January 21, 2021
Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab MonotherapyAjai Chari, Markus Munder, Katja Weisel, et al.
Haematologica|August 20, 2016
Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trialMaximilian Merz, Hans Salwender, Mathias Haenel, et al.
Computers in Biology and Medicine|March 17, 2023
A drug repurposing approach for individualized cancer therapy based on transcriptome sequencing and virtual drug screeningOnat Kadioglu, Faranak Bahramimehr, Mona Dawood, et al.
Leukemia|July 1, 2018
Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myelomaElias K Mai, Thomas Hielscher, Uta Bertsch, et al.
Leukemia|November 4, 2021
Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trialLisa B Leypoldt, Britta Besemer, Anne Marie Asemissen, et al.
Leukemia|February 18, 2021
Selective elimination of immunosuppressive T cells in patients with multiple myelomaMohamed H S Awwad, Abdelrahman Mahmoud, Heiko Bruns, et al.
Haematologica|April 5, 2015
Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trialMaximilian Merz, Hans Salwender, Mathias Haenel, et al.
Pageof 9